| Issuer | % of Class | Filed |
|---|---|---|
|
AEON Biopharma, Inc.
13G
AEON · 00791X209
|
13.0% |
8/21/2026
Event 8/19/2026
|
|
Evolus, Inc.
13G/A
Amendment 2
EOLS · 30052C107
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
Evolus, Inc.
13G/A
Amendment 1
EOLS · 30052C107
|
7.9% |
11/14/2025
Event 9/30/2025
|
|
Evolus, Inc.
13G
EOLS · 30052C107
|
6.3% |
8/18/2025
Event 8/11/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.